IPHA Innate Pharma SA
Price Chart
Executive Summary
HC Wainwright & Co. upgraded Innate Pharma SA (IPHA) from Neutral to Buy on October 29, 2025, setting a $5 price target, implying 173% upside from the current $1.83. The upgrade is part of a three-firm cluster: BTIG reiterated Buy with an $8 target, while Leerink Partners downgraded to Market Perform with a $2 target on September 18. HC Wainwright has a 54% accuracy rate on 13 IPHA calls, above average, and its new Buy stance reverses its September 18 downgrade to Neutral. Consensus is heavily bullish: 7 of 8 analysts rate Buy or Strong Buy, with a mean target of $6 (228% upside). The mean target is above HC Wainwright's $5 PT. EPS estimates for the current fiscal year have been revised down once in the past 30 days, but the +1q EPS estimate improved from -$0.092 to -$0.082. No insider trades or congressional activity are recorded. Institutional activity is mixed: Citadel doubled its position (104.7% increase) while UBS trimmed by 33.8%. The upgrade from a high-accuracy firm reversing a prior downgrade is a significant bullish signal, but the lack of near-term earnings catalysts and mixed institutional flows warrant caution. Bottom line: the upgrade is a strong contrarian vote from a firm with a good track record, but traders should wait for volume confirmation before entering.
Impact Score
Consensus & Targets
Consensus is heavily bullish: 2 Strong Buy, 5 Buy, 1 Hold, 0 Sell, 0 Strong Sell (8 analysts). 87.5% rate Buy or Strong Buy. The direction is strongly bullish, though the upgrade from a previously Neutral firm adds a contrarian element.
Current price: $1.83. Mean target: $6 (228% upside). Median: $6.5. High: $8 (BTIG). Low: $3. HC Wainwright's $5 PT sits below the mean but still implies substantial upside. The wide range ($3-$8) reflects high uncertainty.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-07 | HC Wainwright & Co. | reiterate | Buy | — |
| 2025-10-29 | HC Wainwright & Co. | upgrade | Buy | $5.00 |
| 2025-10-29 | BTIG | reiterate | Buy | $8.00 |
| 2025-09-18 | Leerink Partners | downgrade | Market Perform | $2.00 |
| 2025-09-18 | HC Wainwright & Co. | downgrade | Neutral | — |
| 2025-04-24 | HC Wainwright & Co. | reiterate | Buy | $11.00 |
| 2025-03-28 | HC Wainwright & Co. | reiterate | Buy | $11.50 |
| 2025-02-06 | HC Wainwright & Co. | reiterate | Buy | $11.50 |
| 2025-01-17 | HC Wainwright & Co. | reiterate | Buy | $11.50 |
| 2024-12-09 | HC Wainwright & Co. | reiterate | Buy | $11.50 |
30-day analyst activity: 0 upgrades, 0 downgrades (excluding this cluster). EPS revisions: +1q estimate improved from -$0.092 to -$0.082 (up 10.9%) in the past 30 days, but full-year estimates saw 1 downward revision. The near-term estimate improvement is a positive signal.
Firm Track Record — HC Wainwright & Co.
HC Wainwright & Co. accuracy: 43% on 4605 calls | avg return: 2.5%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 1 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| HC Wainwright & Co. | 54% | 7/13 | 3.5% | above average |
HC Wainwright has a 54% accuracy rate on 13 IPHA calls, with an average return of 3.5%. This is above the firm's overall 43% accuracy on 4,605 calls. Among firms covering IPHA, BTIG (not shown in accuracy data) has the highest PT ($8). HC Wainwright's track record on IPHA is solid, making this upgrade more credible.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $-0.08 | $-0.08 — $-0.08 | $8.0M | ↑0 ↓0 |
| +1y | $-0.63 | $-0.99 — $-0.40 | $64.7M | ↑1 ↓0 |
| 0y | $-0.55 | $-0.65 — $-0.46 | $31.2M | ↑1 ↓0 |
| 0q | $-0.15 | $-0.15 — $-0.15 | $2.6M | ↑0 ↓0 |
Cross-Platform Signals
No insider trades or congressional activity recorded. Institutional activity is mixed: Citadel doubled its position (+104.7%, $43M) while UBS trimmed (-33.8%, $10.8M). No short interest data available. The upgrade from a high-accuracy firm aligns with Citadel's bullish move, but UBS's trimming introduces caution.
Actionable Insight
The upgrade from a high-accuracy firm reversing a prior downgrade is a strong bullish signal. However, the lack of near-term earnings catalysts and mixed institutional flows suggest waiting for volume confirmation above $2.00 before initiating a position.
Documents Analyzed
Report based on filing metadata.
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 24, 2026
16d ago
|
ANALYST-UPGRADE
| $2.07 $1.89 | ▼ −8.70% | ▼ −7.68% | $1.76 (−14.98%) |
|
Apr 24, 2026
6w ago
|
ANALYST-UPGRADE
| $1.41 $1.97 | ▲ +39.72% | ▲ +35.69% | $1.76 (+24.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access